Free Trial

Liminatus Pharma (NASDAQ:LIMN) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

  • Liminatus Pharma (NASDAQ:LIMN) has been downgraded from a "hold" rating to a "sell" rating by Wall Street Zen in a recent research report.
  • The stock opened at $5.93 and has a 52-week trading range of $4.40 to $33.66.
  • Liminatus Pharma is a pre-clinical-stage immuno-oncology company focused on developing innovative cancer therapies.
  • Interested in Liminatus Pharma? Here are five stocks we like better.

Liminatus Pharma (NASDAQ:LIMN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

Liminatus Pharma Price Performance

NASDAQ LIMN opened at $5.93 on Friday. Liminatus Pharma has a 52 week low of $4.40 and a 52 week high of $33.66.

About Liminatus Pharma

(Get Free Report)

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Liminatus Pharma Right Now?

Before you consider Liminatus Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liminatus Pharma wasn't on the list.

While Liminatus Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines